---
title: "武田公司與 Nabla Bio 簽署了多年期的研究合作協議"
description: "田邊製藥與 Nabla Bio 簽署多年研究合作協議"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261045725.md"
published_at: "2025-10-14T11:00:49.000Z"
---

# 武田公司與 Nabla Bio 簽署了多年期的研究合作協議

> 田邊製藥與 Nabla Bio 簽署多年研究合作協議

### Related Stocks

- [4502.JP - Takeda Pharmaceutical Co. Ltd.](https://longbridge.com/zh-HK/quote/4502.JP.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA Accepts Takeda's Oveporexton Application for Priority Review in Narcolepsy Type 1 | The FDA has accepted Takeda's New Drug Application for oveporexton, an investigational therapy for narcolepsy type 1, gr | [Link](https://longbridge.com/zh-HK/news/275421654.md) |
| Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance | Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance | [Link](https://longbridge.com/zh-HK/news/275444067.md) |
| FDA nimmt Zulassungsantrag für Oveporexton von Takeda zur Prüfung an | The FDA has accepted Takeda Pharmaceutical Co. Ltd.'s application for Oveporexton (TAK-861) to treat Type 1 Narcolepsy a | [Link](https://longbridge.com/zh-HK/news/275421640.md) |
| Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up | Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up | [Link](https://longbridge.com/zh-HK/news/274732289.md) |
| Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures | Bio-Rad Laboratories (BIO) has experienced significant share price declines, prompting a reassessment of its valuation.  | [Link](https://longbridge.com/zh-HK/news/275997412.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。